Trial of Apremilast for Oral Ulcers in Behcet's Syndrome


Hatemi G. , Mahr A., Ishigatsubo Y., Song Y., Takeno M., Kim D., ...Daha Fazla

NEW ENGLAND JOURNAL OF MEDICINE, cilt.381, sa.20, ss.1918-1928, 2019 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 381 Konu: 20
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1056/nejmoa1816594
  • Dergi Adı: NEW ENGLAND JOURNAL OF MEDICINE
  • Sayfa Sayıları: ss.1918-1928

Özet

BackgroundThe small-molecule phosphodiesterase 4 inhibitor apremilast modulates cytokines that are up-regulated in Behcet's syndrome. In a phase 2 trial involving patients with Behcet's syndrome, apremilast reduced the incidence and severity of oral ulcers. Data on the efficacy and safety of apremilast in patients with Behcet's syndrome who had active oral ulcers and had not previously received biologic agents are limited.